---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-095628"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2025-07-14T23:59:59+00:00"
generated_at: "2026-05-18T06:50:34.622743+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# FibroGen reduces minimum cash covenant to $18.75M in third amendment to Morgan Stanley financing

## Summary
- Third Amendment to Financing Agreement dated July 14, 2025 lowers required U.S. qualified cash from $22.5M to $18.75M.
- Amendment with lenders managed by Morgan Stanley Tactical Value and agent Wilmington Trust.
- Effective July 14, 2025; no other changes to Financing Agreement terms.

## SEC filing metadata
- accession: 0000950170-25-095628
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2025-07-14T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017025095628/0000950170-25-095628-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017025095628/fgen-20250714.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-095628
- JSON: https://secwatch.observer/filing/0000950170-25-095628.json
- Plain text: https://secwatch.observer/filing/0000950170-25-095628.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.